A point to be noted for current valuations - Although PE is about 35 times (highest in recent times), however the Price to Free Cash Flow is more than 100 times (which is quite higher than industry average of about 50-60). I believe the valuations are currently stretched, however the stock is in upward momentum since the past few months.
Disc: Invested
Price to cashflow from operations is 59.9 which is higher than recent times but not something company hasnt seen. in growth phase and in momentum little stretched price to cashflow from operations should not be a big problem
Attaching herewith a Press Release regarding receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) with Zero 483 observations for the unannounced inspection conducted at Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi between August 05th and 09th, 2024.
Chennai, January 06, 2025: Caplin Point Laboratories Ltd. (“Caplin Point” or the “Company”) (BSE: 524742 | NSE: CAPLIPOINT), announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the recent inspection conducted at Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced USFDA inspection was conducted between August 5th and 9th, 2024 and was concluded with Zero 483 observations, reflecting the company’s commitment to maintaining the highest standards of quality and compliance.
- The subsidiary received final approval for its Abbreviated New Drug Application (ANDA) for Levetiracetam in Sodium Chloride Injection in various dosage forms (500mg/100mL, 1000mg/100mL, and 1500mg/100mL).
- This approval marks the company’s second success in the Ready-To-Use (RTU) Infusion Bag segment.
The approved drug addresses epilepsy-related conditions, with US market sales for this drug estimated at $19 million for the 12 months ending November 2024.